# Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia

> **NCT03610321** · PHASE2,PHASE3 · UNKNOWN · sponsor: **First Affiliated Hospital of Harbin Medical University** · enrollment: 70 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Gefarnate
- **DRUG:** Statin

## Key facts

- **NCT ID:** NCT03610321
- **Lead sponsor:** First Affiliated Hospital of Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03610321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03610321, "Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03610321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*